Q-omics provides the consensus-scored ZNF846 profile across patient tissues and cancer cell-line models. ZNF846 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF846 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, ZNF846 RNA expression shows 20,371 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, LIHC, and UVM as cancer lineages where ZNF846 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF846 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF846 survival associations across molecular data types. ZNF846 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF846 RNA expression–survival associations across cancer types. High ZNF846 expression shows unfavorable associations in KICH and LGG, but favorable associations in HNSC, READ, MESO and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF846 RNA expression.
This table summarizes ZNF846 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF846. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF846 shows lower tumor expression in UCEC, BLCA, BRCA and THCA and higher tumor expression in LIHC and CHOL. The LIHC box plot shows higher ZNF846 RNA expression in tumor versus normal tissue (log2 FC = +0.883, t-test p < 0.001).
This table shows molecular features associated with ZNF846 in patient tissues and cancer cell lines. In patient samples, ZNF846 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF846 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
